Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ivy Micro Cap Growth Fund Class B (IGWBX)

Net Asset Value
1 Day
Overall Morningstar Rating
Small growth
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide growth of capital. The fund seeks to achieve its objective by investing, under normal circumstances, at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of micro capitalization companies. Micro capitalization companies typically are companies with float-adjusted market capitalizations below $1 billion at the time of acquisition. The fund's investment manager, utilizes a bottom-up stock selection process and seeks to invest in securities of companies that it believes exhibit extraordinary earnings growth, earnings surprise potential, fundamental strength and management vision.


1 month-0.93% 3 years+16.78%
3 months+6.87% 5 years+14.92%
1 year+11.05% Since inception+19.47%
Data through --

Peer Comparisonvs. Small growth

Performance 5-yr return+14.92%+17.65%
Expense ratio2.59%1.37%
Risk 5 year sharpe ratio0.871.05
Net assets$229.7M$835.3M
Average market cap$628.6M$2.9B
Average P/E--28.2
Portfolio turnover47%47%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyIvy Funds
Fund manager & tenureJohn Bichelmeyer / 0 Years
Minimal initial investment$750.00
Minimum IRA investment--


U.S. stock95.63%
International stock1.59%
Fixed income0.50%
Top 5 Sectors
Portfolio weighting
Healthcare 14.90%
Hardware 14.00%
Business service 13.23%
Media 10.15%
Consumer service 8.55%
Top 10 Holdings
Portfolio weighting
-- 3.57%
RGEN Repligen Corp2.35%
AERI Aerie Pharmaceuticals Inc1.94%
QDEL Quidel Corp1.81%
TWOU 2U Inc1.81%
CALD Callidus Software Inc1.76%
NLNK NewLink Genetics Corp1.62%
RTRX Retrophin Inc1.58%
PTX Pernix Therapeutics Holdings Inc1.55%
QTWO Q2 Holdings Inc1.55%